111 Capital Invests $790,000 in CVS Health Co. (NYSE:CVS)

111 Capital purchased a new position in shares of CVS Health Co. (NYSE:CVS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 17,597 shares of the pharmacy operator's stock, valued at approximately $790,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CVS. LaFleur & Godfrey LLC grew its holdings in CVS Health by 49.9% during the 4th quarter. LaFleur & Godfrey LLC now owns 4,836 shares of the pharmacy operator's stock worth $217,000 after acquiring an additional 1,610 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of CVS Health by 17.9% in the 4th quarter. Exchange Traded Concepts LLC now owns 17,514 shares of the pharmacy operator's stock valued at $786,000 after buying an additional 2,661 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of CVS Health by 56.1% in the 4th quarter. Blue Trust Inc. now owns 15,099 shares of the pharmacy operator's stock valued at $678,000 after buying an additional 5,426 shares in the last quarter. Stonegate Investment Group LLC boosted its holdings in shares of CVS Health by 14.5% in the 4th quarter. Stonegate Investment Group LLC now owns 9,096 shares of the pharmacy operator's stock valued at $408,000 after buying an additional 1,151 shares in the last quarter. Finally, R Squared Ltd acquired a new position in shares of CVS Health in the 4th quarter valued at $186,000. Institutional investors and hedge funds own 80.66% of the company's stock.

CVS Health Stock Performance

CVS Health stock traded down $0.45 during trading hours on Monday, reaching $63.60. 6,674,441 shares of the stock were exchanged, compared to its average volume of 11,195,184. The stock has a market cap of $80.45 billion, a P/E ratio of 17.38, a P/E/G ratio of 0.98 and a beta of 0.60. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $72.51. The firm's 50 day moving average is $65.54 and its 200 day moving average is $59.74.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.63. The company had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. CVS Health's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.31 EPS. Analysts predict that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 4.18%. CVS Health's payout ratio is currently 63.48%.

Insider Transactions at CVS Health

In other news, SVP James David Clark sold 7,513 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the transaction, the senior vice president now directly owns 8,394 shares of the company's stock, valued at $556,941.90. This represents a 47.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.22% of the company's stock.

Wall Street Analysts Forecast Growth

CVS has been the subject of several research analyst reports. Royal Bank of Canada upped their target price on shares of CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a report on Monday, May 5th. Wells Fargo & Company restated an "overweight" rating and issued a $84.00 target price (up previously from $76.00) on shares of CVS Health in a report on Tuesday, May 6th. Cowen restated a "buy" rating on shares of CVS Health in a report on Monday, May 5th. Truist Financial upped their target price on shares of CVS Health from $82.00 to $84.00 and gave the company a "buy" rating in a report on Monday, May 12th. Finally, JPMorgan Chase & Co. upped their price target on shares of CVS Health from $80.00 to $81.00 and gave the company an "overweight" rating in a research report on Tuesday, February 18th. Two analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $74.75.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.